• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

AKN-028

CAS No. 1175017-90-9

AKN-028 ( —— )

产品货号. M28189 CAS No. 1175017-90-9

AKN-028 是一种口服有效的 FLT3 酪氨酸激酶抑制剂 (IC 50 = 6 nM)。 AKN-028 会导致 FLT3 自磷酸化的剂量依赖性抑制。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥721 有现货
10MG ¥1223 有现货
25MG ¥2527 有现货
50MG ¥3969 有现货
100MG ¥5792 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    AKN-028
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    AKN-028 是一种口服有效的 FLT3 酪氨酸激酶抑制剂 (IC 50 = 6 nM)。 AKN-028 会导致 FLT3 自磷酸化的剂量依赖性抑制。
  • 产品描述
    AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.(In Vitro):AKN-028 triggers apoptosis in MV4-11 by activation of caspase 3 . AKN-028 (10 μM) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11 . Cell Cytotoxicity Assay Cell Line: AML cell line MV4-11. Concentration: 10 μM. Incubation Time: 24 h. Result: Was cytotoxic to primary AML cells, irrespective of FLT3 mutation status and quantitative FLT3 expression.(In Vivo):AKN-028 (15?mg/kg, Subcutaneously injection twice daily) exhibits anti-tumor activities for acute myeloid leukemia (AML) models . Animal Model: Mice based AML and MV4-11 cells . Dosage: 15?mg/kg. Administration: Subcutaneously injection twice daily. Result: Inhibited net growth of one of the primary AML samples (UPN26) in vivo and furthermore reduced the tumor mass of MV4-11 cell line.
  • 体外实验
    AKN-028 (0.1 nM-100 μM; 15 h; mouse embryonal fibroblasts and human acute megakaryoblastic leukemia M07 cells) inhibits FLT3 and KIT autophosphorylation in a dose-dependent manner.AKN-028 (10 μM; 72 h; tumor cell lines) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11. Western Blot Analysis Cell Line:Mouse embryonal fibroblasts either overexpressing FLT-wt, FLT3-TKD or FLT3-ITD and human acute megakaryoblastic leukemia M07 cells overexpressing KIT Concentration:0.1 nM-100 μM Incubation Time:15 hours Result:Inhibited FLT3 and KIT autophosphorylation.Cell Cytotoxicity Assay Cell Line:Tumor cell lines Concentration: 10 μM Incubation Time:72 hours Result:Had cytotoxic activity was highest in MV4-11 and MOLM-13 (IC50<50?nM), followed by the three other AML cell lines (IC50=0.5-6?μM).
  • 体内实验
    AKN-028 (15?mg/kg; i.h.; twice daily, for 6 days; male C57 black mice with MV4-11 xenografts) inhibits growth of primary AML and MV4-11 cells in mice. Animal Model:Male C57 black mice with MV4-11 xenografts Dosage:15 mg/kg Administration:Subcutaneous injection; twice daily, for 6 days Result:Inhibited tumor growth and did not affect body weight.
  • 同义词
    ——
  • 通路
    Angiogenesis
  • 靶点
    FLT
  • 受体
    ——
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1175017-90-9
  • 分子量
    302.33
  • 分子式
    C17H14N6
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO : 125 mg/mL (413.46 mM)
  • SMILES
    NC1=NC=C(N=C1NC1=CC=C2NC=CC2=C1)C1=CC=NC=C1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Morita M, et al. Preliminary preformulation studies of a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new drug development. Chem Pharm Bull (Tokyo). 1995 Mar;43(3):476-82.
产品手册
关联产品
  • 7BIO

    7-bromoindirubin-3'-oxime (7BIO) 是一种不依赖半胱天冬酶的非凋亡细胞死亡诱导剂。 7BIO 是 FLT3、DYRK1A、DYRK2、Aurora B 和 Aurora C 激酶的抑制剂。

  • Pacritinib

    Pacritinib (SB1518) 是 Janus Kinase 2 (JAK2) 和 Fms-Like Tyrosine Kinase-3 (FLT3) 的有效选择性抑制剂,在无细胞测定中 IC50 分别为 23 和 22 nM。

  • (E/Z)-Zotiraciclib

    (E/Z)-Zotiraciclib 有效抑制 CDK2、JAK2 和 FLT3,IC50 分别为 13、73 和 56 nM。